-+ 0.00%
-+ 0.00%
-+ 0.00%

CLOUDBREAK PHARMA ANNOUNCES TOP-LINE RESULTS FROM ITS PHASE 3 STUDY OF CBT-001 IN PATIENTS WITH PTERYGIUM

Reuters·11/05/2026 01:02:01